News

Discover the latest news stories, blog posts and publications from Cobra's expert team

Home / News

or

Posts about

Gene Therapy

Charles River Laboratories Completes the Acquisition of Cognate BioServices

Featured, Gene Therapy, cell therapy, acquisition, Charles River

The acquisition establishes Charles River as a premier scientific partner for cell and gene therapy development, testing, and manufacturing, providing clients with an integrated solution from basic research and discovery through CGMP production.

Charles River to Acquire Cognate BioServices to Create a Premier Scientific Partner for Cell and Gene Therapy Development

Gene Therapy, cell therapy, acquisition, Charles River

Significantly Expands Charles River’s Scientific Capabilities in the High-Growth Cell and Gene Therapy Sector & Combines Cognate’s Comprehensive Cell and Gene Therapy CDMO Capabilities to Establish an Integrated Solution from Discovery through CGMP Manufacturing

Cognate BioServices, and its gene therapy division Cobra Biologics Announce Major Expansion of Manufacturing Facilities in US and Europe

Gene Therapy, ATMP, expansion, cell therapy, Cognate BioServices

This includes a four-fold increase in HQ (High Quality) DNA manufacturing capacity alongside new clinical and commercial GMP DNA facilities at its European facilities

CombiGene and Cobra Biologics sign agreement to secure GMP production of plasmids for production of CombiGene's gene therapy CG01

Gene Therapy, CombiGene, plasmid dna, CG01, epilepsy

The agreement is part of preparations for GMP production of material for the first clinical study of CG01

Cobra Biologics completes production of Master Cell Banks for CombiGene’s epilepsy gene therapy drug candidate

Gene Therapy, CombiGene, plasmid dna, CG01, epilepsy

Foundation for future commercial supply of CG01 secured with delivery of three Master Cell Banks

Cobra Biologics delivers final plasmids for production of CG01 in CombiGene's epilepsy project

Gene Therapy, CombiGene, plasmid dna, CG01, epilepsy

Further milestone paves the way for production of novel gene therapy drug candidate designed to treat drug-resistant focal epilepsy

Cobra Biologics successfully completes key milestone in CombiGene’s epilepsy project CG01 with delivery of first DNA plasmid

Gene Therapy, News, CombiGene, plasmid dna

Production method of plasmids developed and first plasmid produced for gene therapy drug candidate aimed at treating drug resistant focal epilepsy Production method of plasmids developed and first plasmid produced for gene therapy drug candidate aimed at treating drug resistant focal epilepsy

Cognate BioServices closes Series B and completes acquisition of Cobra Biologics

Gene Therapy, General, cell therapy, acquisition, Cognate BioServices

This transaction further supports Cognate's mission to meet the needs of the ultimate consumer of its services — the patients with unmet medical needs

Cognate BioServices announces acquisition of Cobra Biologics

Gene Therapy, General, cell therapy, acquisition, Cognate BioServices

Transformative acquisition creates global cell and gene therapy manufacturing services platform for both clinical and commercial products aaaaa

CPI Accelerates Gene Therapy Development with Robust Adeno-Associated Virus Purification System in Partnership with Cobra Biologics and GE Healthcare

Viral Vectors, Gene Therapy, Collaboration, CPI, AAV, Innovate, Centre for Process Innovation, GE Healthcare, adeno-associated virus

The new process will remove a significant bottleneck in the development of gene therapies, and enable these innovative products to be brought to market more quickly. CPI has announced the success of its CRD IUK project to develop a scalable, cost-effective purification process for adeno-associated viruses (AAVs), in partnership with Cobra Biologics and GE Healthcare Life Sciences. The new process will remove a significant bottleneck in the development of gene therapies, and enable these innovative products to be brought to market more quickly.

CombiGene signs agreement with Cobra Biologics for production of candidate drug CG01

Viral Vectors, Gene Therapy, Collaboration, AAV, CombiGene

Collaboration supports progression of Epilepsy Gene Therapy toward clinical trials (Svensk version nedan)

1 2 3